Portal de investigación
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ABIVAX SA
Cita
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis. (ABX464-105). ABIVAX SA. 2024IP:MARISA IBORRA COLOMINO.